Detail Information of Exogenous Modulation
General Information of Drug Transporter (DT) | |||||
---|---|---|---|---|---|
DT ID | DTD0104 Transporter Info | ||||
Gene Name | SLC16A13 | ||||
Transporter Name | Monocarboxylate transporter 13 | ||||
Gene ID | |||||
UniProt ID | |||||
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM) | |||||
---|---|---|---|---|---|
Chemical Compound |
|||||
DT Modulation1 |
Benzo(a)pyrene results in decreased methylation of SLC16A13 exon | [15] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Benzo(a)pyrene results in increased methylation of SLC16A13 promoter | [15] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
1-Methyl-3-isobutylxanthine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F results in increased expression of SLC16A13 mRNA | [11] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
abrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
abrine results in decreased expression of SLC16A13 mRNA | [12] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
aristolochic acid I |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
aristolochic acid I results in decreased expression of SLC16A13 mRNA | [13] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bisphenol A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bisphenol A results in increased expression of SLC16A13 mRNA | [16] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bisphenol F |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F results in increased expression of SLC16A13 mRNA | [11] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
CGP 52608 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
CGP 52608 promotes the reaction RORA protein binds to SLC16A13 gene | [17] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
chromium hexavalent ion |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
zinc chromate results in increased abundance of chromium hexavalent ion which results in decreased expression of SLC16A13 mRNA | [18] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Cisplatin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cisplatin co-treated with jinfukang results in increased expression of SLC16A13 mRNA | [7] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Dexamethasone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F results in increased expression of SLC16A13 mRNA | [11] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Diazinon |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Diazinon results in increased methylation of SLC16A13 gene | [19] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
di-n-butylphosphoric acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
di-n-butylphosphoric acid affects the expression of SLC16A13 mRNA | [20] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
epigallocatechin gallate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
potassium chromate(VI) co-treated with epigallocatechin gallate results in decreased expression of SLC16A13 mRNA | [21] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
ferrous chloride |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
ferrous chloride results in decreased expression of SLC16A13 mRNA | [22] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Indomethacin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F results in increased expression of SLC16A13 mRNA | [11] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
nickel sulfate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
nickel sulfate results in increased expression of SLC16A13 mRNA | [23] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Okadaic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Okadaic Acid results in increased expression of SLC16A13 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
perfluorooctanoic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
perfluorooctanoic acid results in increased expression of SLC16A13 mRNA | [25] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
potassium chromate(VI) |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
potassium chromate(VI) co-treated with epigallocatechin gallate results in decreased expression of SLC16A13 mRNA | [21] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
potassium chromate(VI) results in decreased expression of SLC16A13 mRNA | [21] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
quercitrin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
quercitrin results in decreased expression of SLC16A13 mRNA | [5] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
sodium arsenite |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
sodium arsenite results in increased abundance of Arsenic which results in decreased expression of SLC16A13 mRNA | [14] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
zinc chromate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
zinc chromate results in increased abundance of chromium hexavalent ion which results in decreased expression of SLC16A13 mRNA | [18] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Approved Drug |
|||||
Fenofibrate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fenofibrate increases the expression of SLC16A13 | [1] | |||
Acetaminophen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Acetaminophen inhibits the expression of SLC16A13 | [2] | |||
Sunitinib |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sunitinib increases the expression of SLC16A13 | [3] | |||
Drug in Phase 2 Trial |
|||||
Bisphenol A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bisphenol A increases the expression of SLC16A13 | [10] | |||
Natural Product |
|||||
Quercitrin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Quercitrin inhibits the expression of SLC16A13 | [5] | |||
Tobacco Smoke Pollution |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tobacco Smoke Pollution increases the expression of SLC16A13 | [9] | |||
Traditional Medicine |
|||||
Jinfukang |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Jinfukang increases the expression of SLC16A13 | [7] | |||
Mycotoxins |
|||||
Aflatoxin B1 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Aflatoxin B1 inhibits the expression of SLC16A13 | [4] | |||
Carcinogen |
|||||
Benzo(a)pyrene |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzo(a)pyrene inhibits the expression of SLC16A13 | [8] | |||
Arsenic |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
sodium arsenite results in increased abundance of Arsenic which results in decreased expression of SLC16A13 mRNA | [14] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Health and Environmental Toxicant |
|||||
tris(1,3-dichloro-2-propyl)phosphate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC16A13 | [6] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.